Long‐Term Outcomes in Patients With Hemorrhagic Moyamoya Disease Combined With Hypertension After Encephaloduroarteriosynangiosis
Open Access
- 17 June 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e039054
Abstract
Background: Although hypertension is prevalent in adults with moyamoya disease (MMD) and intracranial hemorrhage significantly worsens prognosis, the impact of hypertension on long‐term outcomes after encephaloduroarteriosynangiosis in hemorrhagic MMD remains unclear; this retrospective cohort study used propensity score matching to compare outcomes between hypertensive and nonhypertensive patients and preliminarily assess the role of blood pressure management. Methods: After propensity score matching, long‐term outcomes post‐ encephaloduroarteriosynangiosis in patients with hemorrhagic MMD with hypertension from January 2010 to December 2018 were analyzed. The clinical and radiological data were collected. Kaplan–Meier curves evaluated the relationship between recurrence‐free survival, overall survival (OS), and hypertension. Univariate and multivariate Cox regression assessed independent factors influencing hematoma recurrence‐free survival and OS. Subgroup analysis of patients with hemorrhagic MMD with hypertension assessed the impact of different blood management on long‐term outcomes. Results: Kaplan–Meier curves showed a significant correlation between hypertension and decreased hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014) during follow‐up. The 5‐year recurrence‐free survival rate did not significantly differ between hypertensive and nonhypertensive groups ( P =0.77). Hypertension was associated with reduced 10‐year hematoma recurrence‐free survival ( P =0.004) and OS ( P =0.014). In multivariate analysis, hypertension ( P =0.015), perioperative complications ( P =0.003), and choroidal anastomosis ( P =0.0008) significantly influenced hematoma recurrence‐free survival. Analysis of OS revealed significant differences for hypertension ( P =0.018), follow‐up duration ( P P =0.041), and initial mRS ( P P =0.049) but did not improve OS ( P =0.31). Conclusions: This study highlights significant differences in hematoma recurrence‐free survival and OS between patients with hemorrhagic MMD with and without hypertension. A subgroup analysis of those with hypertension showed that optimal blood pressure control notably lowered hematoma recurrence but did not improve OS. For patients with hemorrhagic MMD with hypertension, optimizing blood pressure alone may be insufficient, emphasizing the importance of personalized integrated strategies for this patient subgroup.Keywords
This publication has 38 references indexed in Scilit:
- Identification of associations and distinguishing moyamoya disease from ischemic strokes of other etiologies: A retrospective case-control studyAnnals of Medicine & Surgery, 2022
- Validation of choroidal anastomosis on high-resolution magnetic resonance imaging as an imaging biomarker in hemorrhagic moyamoya diseaseEuropean Radiology, 2021
- Treatment course and outcomes after revascularization surgery for moyamoya disease in adultsJournal of Neurology, 2018
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Hypertension and Cerebrovascular DysfunctionCell Metabolism, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- MoyamoyaArchives of Neurology, 2001
- A Co-Operative Study: Clinical Characteristics of 334 Korean Patients with Moyamoya Disease Treated at Neurosurgical Institutes (1976-1994)Acta Neurochirurgica, 2000
- Efficacy of Direct Revascularization in Adult Moyamoya Disease: Haemodynamic Evaluation by Positron Emission TomographyActa Neurochirurgica, 1999
- Cerebrovascular "Moyamoya" DiseaseArchives of Neurology, 1969